Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, John Efthimiou, William Pullman, Hubert Schrezenmeier, Jens Panse

Blood (2024) 144 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2024-205866

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

A Single-Centre Experience of Methotrexate in the Management of Pure Red Cell Aplasia and Pure White Cell Aplasia

Laura Batey, Richard J. Kelly, Talha Munir, Petra Muus, Abraham Mullasseril Varghese, Louise M Arnold, Catherine Barnfield, Isla Storey, Nora Youngs, Jessica Molyneux, Morag Griffin

Blood (2024) 144 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2024-203945

Published: 2024

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

Alexandra Pike, Stephen John Richards, Claire E McKinley, Louise M Arnold, Abraham Mullasseril Varghese, Talha Munir, Petra Muus, Peter Hillmen, Morag Griffin, Richard J Kelly, Darren Newton

Blood (2023) 142 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2023-188755

Published: 2023

Journal Articles

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Richard J. Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Kosalai Mohan, Brian Senk, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2023) 142 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2023-188671

Published: 2023

Journal Articles

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Blood (2023) 142 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2023-190393

Published: 2023

Journal Articles

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Morag Griffin, Petra Muus, Talha Munir, Sateesh Nagumantry, Alexandra Pike, Louise Arnold, Briony Forrest, Catherine Barnfield, Nicola Houghton, Nora Youngs, Richard Kelly

Blood (2023) 141 (1): 116–120.

https://doi.org/10.1182/blood.2022017266

Published: 2023

Journal Articles

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Richard Kelly, Matthew Holt, Jennifer Vidler, Louise Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Roochi Trikha, Austin Kulasekararaj, Lindsay Mitchell, Shreyans Ghandi

Blood (2022) 140 (Supplement 1): 5792–5794.

https://doi.org/10.1182/blood-2022-167725

Published: 2022

Journal Articles

Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab: An Interim Analysis

Morag Griffin, Shreyans Gandhi, Eden Hicks, Deepak Jain, Richard Kelly, Talha Munir, Petra Muus, Masayo Ogawa, Roochi Trikha, Ji Yu, Austin Kulasekararaj

Blood (2022) 140 (Supplement 1): 2928–2930.

https://doi.org/10.1182/blood-2022-159498

Published: 2022

Journal Articles

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Richard Kelly, Nicola Houghton, Talha Munir, Petra Muus, Nora Youngs, Lisa Aurand, Bradley Dain, Rodrigo Pavani, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2022) 140 (Supplement 1): 8174–8175.

https://doi.org/10.1182/blood-2022-166547

Published: 2022

Journal Articles

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Rachael Jones, BSc, Petra Muus, MD PhD, Talha Munir, MBBS, Alexandra Pike, MBBS, Louise Arnold, Jeanifer Gachev, Briony Forrest, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140256

Published: 2020

Journal Articles

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Louise Arnold, Ray Borrow, PhD FRCPath, Kathryn Riley, Talha Munir, MBBS, Richard Kelly, BSc, MD, Rachael Jones, BSc, Jeanifer Gachev, Briony Forrest, Alexandra Pike, MBBS, Petra Muus, MD PhD, Peter Hillmen, MBChB, PhD, Morag Griffin, MBChB, FRCPath

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141780

Published: 2020

Journal Articles

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Louise Arnold, Richard Kelly, BSc, MD, Talha Munir, MBBS, Petra Muus, MD PhD, Alexandra Pike, MBBS, Kathryn Riley, Briony Forrest, Jeanifer Gachev, Morag Griffin, MBChB, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141769

Published: 2020

Journal Articles

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Jie Jiang, PhD, Simon Slade, BSc, Austin Kulasekararaj, MD MRCP, FRCPath, Victoria Potter, BSc, MBBS, FRCPA, Varun Mehra, MBBS,MRCP,FRCPath, Petra Muus, MD PhD, Andrea Da Silva, MBBS, Sudarshan Gurung, MBBS, MRCP, Alice Mason, B.Pharm, Aytug Kizilors, PhD, Nicholas Lea, PhD, Sahar Mansour, MD, Robin M. Ireland, MBBS, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Judith Marsh, MD FRCPath

Blood (2019) 134 (Supplement_1): 3749.

https://doi.org/10.1182/blood-2019-130754

Published: 2019

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Blood (2017) 130 (Supplement 1): 3850.

https://doi.org/10.1182/blood.V130.Suppl_1.3850.3850

Published: 2017

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

NARROW

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

A Single-Centre Experience of Methotrexate in the Management of Pure Red Cell Aplasia and Pure White Cell Aplasia

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations

52-Week Open-Label Extension Data from a Phase 2 Study Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switched from Eculizumab

Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab: An Interim Analysis

A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab

Incomplete Complement Inhibition in Patients with PNH on Eculizumab - 5 Year Experience from the National PNH Service Leeds

Management of Meningococcal Disease Risk in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) on Complement Inhibitors: 18 Years' Experience from the UK National PNH Service in Leeds

Thrombotic Events with Neisseria Meningitidis Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria, UK Experience

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only